MAximising Therapeutic Utility in Rheumatoid Arthritis  

Highlights and News

Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue - Nature
Automated multi-scale computational pathotyping (AMSCP) of inflamed synovial tissue  Nature
Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition - Frontiers
Deciphering the molecular landscape of rheumatoid arthritis offers new insights into the stratified treatment for the condition  Frontiers
Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts - The Lancet
Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts  The Lancet
Clinical implications of synovial tissue phenotypes in rheumatoid arthritis - Frontiers
Clinical implications of synovial tissue phenotypes in rheumatoid arthritis  Frontiers
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial - Nature
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial  Nature
(PDF) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - researchgate.net
(PDF) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial  researchgate.net
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials - The Lancet
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials  The Lancet
Oral Presentation Abstracts - 2024 - International Journal of Rheumatic Diseases - Wiley Online Library
Oral Presentation Abstracts - 2024 - International Journal of Rheumatic Diseases  Wiley Online Library
Are innovation and new technologies in precision medicine paving a new era in patients centric care? - Journal of Translational Medicine
Are innovation and new technologies in precision medicine paving a new era in patients centric care?  Journal of Translational Medicine
Clinical Applications of Synovial Biopsy - Frontiers
Clinical Applications of Synovial Biopsy  Frontiers
Rheumatoid arthritis - The Lancet
Rheumatoid arthritis  The Lancet
Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics - Nature
Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics  Nature
Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy - Frontiers
Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy  Frontiers
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial - The Lancet
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial  The Lancet
Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis - Nature
Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis  Nature
Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis - Frontiers
Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis  Frontiers
Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis - Nature
Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis  Nature
Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes - Frontiers
Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes  Frontiers
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients - Frontiers
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients  Frontiers
Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs - Frontiers
Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs  Frontiers
Table 1 Identification of poor prognostic factors in randomized trials... - researchgate.net
Table 1 Identification of poor prognostic factors in randomized trials...  researchgate.net

The MATURA consortium includes academic groups and industry partners working together to identify and test biomarkers
predictive of response to biological therapy in patients with rheumatoid arthritis
Home | Copyright © Experimental Medicine & Rheumatology Department, Queen Mary University London, 2015 - 2025 | Sitemap